TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03188835

Intervention type: RADIATION
Group type: OTHER
Intervention: 18FDG
Description: I.v. injection of 18-fluorodeoxyglucose (18FDG) will be performed, followed by 30 min dynamic and 50 min wholebody PET/CT scanning.

Intervention type: RADIATION
Group type: OTHER
Intervention: 18FDG
Description: I.v. injection of 18-fluorodeoxyglucose (18FDG) will be performed, followed by 30 min dynamic and 50 min wholebody PET/CT scanning.
Study: NCT00083603

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Empty TBC-FPV
Description: Empty FPV 10\^9 pfu/2mL administered as two separate 1 mL intramuscular injections, one into each deltoid.
Study: NCT03188835

Intervention type: RADIATION
Group type: OTHER
Intervention: 18FDG
Description: I.v. injection of 18-fluorodeoxyglucose (18FDG) will be performed, followed by 30 min dynamic and 50 min wholebody PET/CT scanning.

Intervention type: RADIATION
Group type: OTHER
Intervention: 11C-acetate
Description: i.v. injection of 11C-acetate will be performed, followed by 20 min dynamic PET/CT scanning
Study: NCT00083603

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Empty TBC-FPV
Description: Empty FPV 10\^9 pfu/2mL administered as two separate 1 mL intramuscular injections, one into each deltoid.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Empty TBC-FPV
Description: Empty FPV 10\^9 pfu/2mL administered as two separate 1 mL intramuscular injections, one into each deltoid.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Empty TBC-FPV
Description: Empty FPV 10\^9 pfu/2mL administered as two separate 1 mL intramuscular injections, one into each deltoid.
Study: NCT03188835

Intervention type: RADIATION
Group type: OTHER
Intervention: 11C-acetate
Description: i.v. injection of 11C-acetate will be performed, followed by 20 min dynamic PET/CT scanning

Intervention type: RADIATION
Group type: OTHER
Intervention: 11C-acetate
Description: i.v. injection of 11C-acetate will be performed, followed by 20 min dynamic PET/CT scanning

Intervention type: RADIATION
Group type: OTHER
Intervention: [3-3H]-glucose
Description: i.v. administration of 1.5 uCi/min of \[3-3H\]-glucose
Study: NCT00859404

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: oglemilast
Description: Tablet oglemilast or placebo once a day, for 12 weeks
Study: NCT03188835

Intervention type: RADIATION
Group type: OTHER
Intervention: [3-3H]-glucose
Description: i.v. administration of 1.5 uCi/min of \[3-3H\]-glucose

Intervention type: RADIATION
Group type: OTHER
Intervention: [3-3H]-glucose
Description: i.v. administration of 1.5 uCi/min of \[3-3H\]-glucose

Intervention type: OTHER
Group type: OTHER
Intervention: [U-13C]-palmitate
Description: i.v. administration of 0.08 umol/kg/min of \[U-13C\]-palmitate
Study: NCT00083603

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Empty TBC-FPV
Description: Empty FPV 10\^9 pfu/2mL administered as two separate 1 mL intramuscular injections, one into each deltoid.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Empty TBC-FPV
Description: Empty FPV 10\^9 pfu/2mL administered as two separate 1 mL intramuscular injections, one into each deltoid.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rMVA-HIV (rMVA-HIV env/gag + rMVA-HIV tat/rev/nef-RT)
Description: rMVA 10\^8 pfu /2mL administered in each deltoid

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rMVA-HIV (rMVA-HIV env/gag + rMVA-HIV tat/rev/nef-RT)
Description: rMVA 10\^9 pfu /2mL administered in each deltoid

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rMVA-HIV (rMVA-HIV env/gag + rMVA-HIV tat/rev/nef-RT)
Description: rMVA 10\^9 pfu /2mL administered in each deltoid

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rMVA-HIV (rMVA-HIV env/gag + rMVA-HIV tat/rev/nef-RT)
Description: rMVA 10\^9 pfu /2mL administered in each deltoid

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rMVA-HIV (rMVA-HIV env/gag + rMVA-HIV tat/rev/nef-RT)
Description: rMVA 10\^9 pfu /2mL administered in each deltoid

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: TBC-MVA and TBC-FPV
Description: Empty MVA 10\^7 pfu/2mL administered into each deltoid

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: TBC-MVA and TBC-FPV
Description: Empty MVA 10\^8 pfu/2mL administered into each deltoid

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: TBC-MVA and TBC-FPV
Description: Empty MVA 10\^9 pfu/2mL administered into each deltoid

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: TBC-MVA and TBC-FPV
Description: Empty MVA 10\^9 pfu/2mL administered into each deltoid

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: TBC-MVA and TBC-FPV
Description: Empty MVA 10\^9 pfu/2mL administered into each deltoid

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: TBC-MVA and TBC-FPV
Description: Empty MVA 10\^9 pfu/2mL administered into each deltoid
Study: NCT02029157

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARQ197

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02895828

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core Stabilization Exercise
Description: the participants asked to performed CSE program, 20 min/session, 2 session/week, 10 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: General Strengthening Exercise
Description: the participants asked to performed GSE program, 20 min/session, 2 session/week, 10 weeks
Study: NCT01374269

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise program
Description: Standardize the intervention programs Exercise program includes: physical agents, massage of myofascial points, stretching and strengthening exercises, cycloergometer or band aerobic exercises. 12 sessions, 3 per week.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NSAID (Nonsteroidal anti-inflammatory drugs)
Description: The second group was treated for 10 days with NSAIDs (naproxen 500 mg/d or celecoxib 200 mg/d) according to the indications and contraindications. The patients kept a journal stating whether they had taken the drug and any adverse reactions. If the pain intensity of any participant increased, acetaminophen (1.5 - 2.0 g/d) was proposed as a rescue procedure.
Study: NCT02792699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABP 798
Description: Supplied as a 10 mg/mL liquid concentrate for intravenous (IV) administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABP 798
Description: Supplied as a 10 mg/mL liquid concentrate for intravenous (IV) administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab (US)
Description: Supplied as a 10 mg/mL liquid concentrate for IV administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab (EU)
Description: Supplied as a 10 mg/mL liquid concentrate for IV administration.
Study: NCT01807247

Intervention type: PROCEDURE
Intervention: Intensive lower limbs muscles strengthening
Study: NCT03188835

Intervention type: OTHER
Group type: OTHER
Intervention: [U-13C]-palmitate
Description: i.v. administration of 0.08 umol/kg/min of \[U-13C\]-palmitate

Intervention type: OTHER
Group type: OTHER
Intervention: [U-13C]-palmitate
Description: i.v. administration of 0.08 umol/kg/min of \[U-13C\]-palmitate
Study: NCT01807247

Intervention type: PROCEDURE
Intervention: Intensive lower limbs muscles strengthening

Intervention type: PROCEDURE
Intervention: Intensive lower limbs muscles strengthening
Study: NCT02990780

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Conventionally fractionated concurrent chemo-radiotherapy
Description: 5Fx/W,2Gy/Fx,Dt:PTV-G:60Gy/30F/6W.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Accelerated hypofractionated concurrent chemo-radiotherapy
Description: 5Fx/W,2.5Gy/Fx,Dt:PTV-G:55Gy/22F/4.4W.
Study: NCT01823601

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Management Program
Description: Consists in 10 Sessions of 120 minutes of duration, to train diaphragmatic breathing; autogenic training of muscle relaxation; progressive self-focus meditation and cognitive-behavioral training.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Seminars in Health
Description: Volunteers that participate in 10 weekly sessions of seminars in health
Study: NCT03486366

Intervention type: OTHER
Group type: OTHER
Intervention: non interventional trial
Description: other

Intervention type: OTHER
Group type: OTHER
Intervention: non interventional trial
Description: other
Study: NCT05976126

Intervention type: OTHER
Intervention: Determination of dioxins (PCDD/Fs), polychlorinated biphenyls (PCBs) and trace elements
Description: Peripheral blood (about 100 mL in several aliquots) was collected from the volunteers, in the early morning, in blood collection tubes (SST II Advance Tubes, BD Vacutainer). The samples were left for approximately 50 min, then the serum was separated from whole blood by centrifugation at 2,000 rcf for 10 min at 4 °C and then aliquots were stored at -80°C until analysis.

Intervention type: OTHER
Intervention: Determination of dioxins (PCDD/Fs), polychlorinated biphenyls (PCBs) and trace elements
Description: Peripheral blood (about 100 mL in several aliquots) was collected from the volunteers, in the early morning, in blood collection tubes (SST II Advance Tubes, BD Vacutainer). The samples were left for approximately 50 min, then the serum was separated from whole blood by centrifugation at 2,000 rcf for 10 min at 4 °C and then aliquots were stored at -80°C until analysis.

Intervention type: OTHER
Intervention: Determination of dioxins (PCDD/Fs), polychlorinated biphenyls (PCBs) and trace elements
Description: Peripheral blood (about 100 mL in several aliquots) was collected from the volunteers, in the early morning, in blood collection tubes (SST II Advance Tubes, BD Vacutainer). The samples were left for approximately 50 min, then the serum was separated from whole blood by centrifugation at 2,000 rcf for 10 min at 4 °C and then aliquots were stored at -80°C until analysis.
Study: NCT04228497

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: gastric ultrasound
Description: Children in both groups will be scanned in two positions: supine position and right lateral position (RLP) one and two hours following the clear fluid intake and before admission to the operation room in groups 1 and 2 respectively. Gastric antrum will be located in the sagittal plane with simultaneous identification of left lobe of the liver and the descending abdominal aorta or inferior vena cava.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: gastric ultrasound
Description: Children in both groups will be scanned in two positions: supine position and right lateral position (RLP) one and two hours following the clear fluid intake and before admission to the operation room in groups 1 and 2 respectively. Gastric antrum will be located in the sagittal plane with simultaneous identification of left lobe of the liver and the descending abdominal aorta or inferior vena cava.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: the clear fluid intake
Description: the clear fluid intake

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: the clear fluid intake
Description: the clear fluid intake
Study: NCT01740050

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Very Low Calorie Diet (VLCD)
Description: One subject group will lose 10% of initial body weight using a VLCD. There are no risks for the subjects in consuming the VLCD (Modifast, together with the recommended fruit and vegetables) as the macronutrient composition and vitamins/minerals content meet the Dutch recommended daily allowance.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RYGB

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LAGB
Study: NCT02112487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macitentan
Description: 10 mg once daily
Study: NCT04538183

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: WO 5000
Description: WO 5000

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: WO 5001
Description: WO 5001
Study: NCT01582152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPI287
Description: Phase I Starting Dose: 160 mg/m2 given by vein on Day 1 every three weeks of a 42 Day cycle.~Phase II Starting Dose: Maximum Tolerated Dose (MTD) from Phase I.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Arm A + B: 10 mg/kg by vein every 2 weeks of a 42 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Arm A + B: 10 mg/kg by vein every 2 weeks of a 42 day cycle.
Study: NCT03188835

Intervention type: OTHER
Group type: OTHER
Intervention: 2H-Glycerol
Description: i.v. administration of 0.05 µmol/kg/min of 2H-glycerol

Intervention type: OTHER
Group type: OTHER
Intervention: 2H-Glycerol
Description: i.v. administration of 0.05 µmol/kg/min of 2H-glycerol

Intervention type: OTHER
Group type: OTHER
Intervention: 2H-Glycerol
Description: i.v. administration of 0.05 µmol/kg/min of 2H-glycerol

Intervention type: DEVICE
Group type: OTHER
Intervention: MRI/MRS
Description: Visceral and cervico-thoracic MRI and MRS acquisition.

Intervention type: DEVICE
Group type: OTHER
Intervention: MRI/MRS
Description: Visceral and cervico-thoracic MRI and MRS acquisition.

Intervention type: DEVICE
Group type: OTHER
Intervention: MRI/MRS
Description: Visceral and cervico-thoracic MRI and MRS acquisition.

Intervention type: DEVICE
Group type: OTHER
Intervention: Electromyogram (EMG)
Description: Skeletal muscle activity and shivering intensity will be measured by electromyography using surface electrodes

Intervention type: DEVICE
Group type: OTHER
Intervention: Electromyogram (EMG)
Description: Skeletal muscle activity and shivering intensity will be measured by electromyography using surface electrodes

Intervention type: DEVICE
Group type: OTHER
Intervention: Electromyogram (EMG)
Description: Skeletal muscle activity and shivering intensity will be measured by electromyography using surface electrodes

Intervention type: DEVICE
Group type: OTHER
Intervention: DXA
Description: Lean mass will be determined by dual-energy X-ray absorptiometry

Intervention type: DEVICE
Group type: OTHER
Intervention: DXA
Description: Lean mass will be determined by dual-energy X-ray absorptiometry

Intervention type: DEVICE
Group type: OTHER
Intervention: DXA
Description: Lean mass will be determined by dual-energy X-ray absorptiometry

Intervention type: DEVICE
Group type: OTHER
Intervention: Indirect calorimetry
Description: VCO2 will be measured by indirect calorimetry between 15 and 20 min every hour until time 180.

Intervention type: DEVICE
Group type: OTHER
Intervention: Indirect calorimetry
Description: VCO2 will be measured by indirect calorimetry between 15 and 20 min every hour until time 180.

Intervention type: DEVICE
Group type: OTHER
Intervention: Indirect calorimetry
Description: VCO2 will be measured by indirect calorimetry between 15 and 20 min every hour until time 180.
Study: NCT02180867

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib Hydrochloride
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib Hydrochloride
Description: Given PO

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery
Study: NCT03815331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xiaflex®
Description: medication indicated for the treatment of adult men with Peyronie's disease with a palpable plaque and curvature deformity of at least 30 degrees at the start of therapy. Xiaflex belongs to a family of enzymes called collagenases. Collagenases are proteinases that hydrolyze collagen in its native triple helical conformation under physiological conditions, resulting in lysis of collagen deposits. The signs and symptoms of Peyronie's disease are caused by a collagen plaque. Injection of XIAFLEX into a Peyronie's plaque, which is comprised mostly of collagen, may result in enzymatic disruption of the plaque. Following this disruption of the plaque, penile curvature deformity and patient bother caused by Peyronie's disease are reduced

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aveed
Description: Aveed® is an FDA-approved medication for treatment of hypogonadism (low testosterone). It is not approved for the treatment of Peyronie's Disease. Aveed® 750 mg/3mL injection will be placed intramuscularly at the beginning of study, at four weeks, at 10 weeks thereafter.
Study: NCT02180867

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery
Study: NCT04012775

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Humulin® NPH
Description: 4 weeks of glucose-level based dose titration, 24 weeks of treatment with stable doses
Study: NCT03047629

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ENT-01
Description: Daily dosing with ENT-01. ENT-01 is an orally administered proprietary substance formulated as a small 25mg coated tablet. Dosing will range from 25-200mg, and the dose will be taken upon awakening on an empty stomach with 8oz water simultaneous to dopamine.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily dosing with a placebo
Study: NCT03259412

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish Oil
Description: Fish Oil Capsule
Study: NCT04012775

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Insulin Rinsulin® NPH
Description: 4 weeks of glucose-level based dose titration, 24 weeks of treatment with stable doses
Study: NCT03259412

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Olive Oil capsule manufactured to mimic fish oil capsule
Study: NCT03267667

Intervention type: DIAGNOSTIC_TEST
Intervention: 2D Echocardiography and cardiac MRI
Description: imaging of right ventricle by both modalities to assess right ventricle function accurately

Intervention type: DIAGNOSTIC_TEST
Intervention: 2D Echocardiography and cardiac MRI
Description: imaging of right ventricle by both modalities to assess right ventricle function accurately
Study: NCT01257568

Intervention type: DEVICE
Group type: OTHER
Intervention: Rejuvenate Modular Hip
Description: Rejuvenate Modular Hip
Study: NCT04216784

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Furosemide Injection
Description: Patient will receive furosemide intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Furosemide Injection
Description: Patient will receive furosemide intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albumin Human
Description: Patient will receive albumin (25%) 12.5 gm intravenously
Study: NCT02019108

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive walking program with toe-out gait modification
Description: Participants in this study group will perform continuous treadmill walking for a minimum of 30 minutes at each session, but the emphasis will be to increase toe-out angle by 10 degrees over that exhibited at baseline. A mirror will be provided for biofeedback and participants will be instructed on its use for achieving the target toe-out angle. Increased walking time and distance will be encouraged the same as for the control group.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Progressive walking program
Description: At each scheduled visit, participants will perform treadmill walking for a minimum of 30 minutes depending on the individual's baseline activity level and the stage of the intervention. Emphasis will be solely on increasing walking time and distance to achieve the target of a 40% increase in daily activity.
Study: NCT01801748

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: oral wheat challenge
Study: NCT01657890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isavuconazole
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isavuconazole
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isavuconazole
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isavuconazole
Description: oral
Study: NCT01349361

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Daylight mediated photodynamic therapy
Study: NCT01576419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PG201 tablet
Description: One PG201 tablet and one celecoxib placebo capsule(after breakfast, in 30minutes), One PG201 tablet and one celecoxib placebo capsule(after dinner, in 30minutes)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celebrex capsule
Description: One celecoxib capsule and one PG201 placebo tablet(after breakfast, in 30minutes), one celecoxib placebo capsule and one PG201 placebo tablet(after dinner, in 30minutes)
Study: NCT02182206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBF 1120
Study: NCT01887015

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal high flow cannula (OptiflowTM, MR850 heated humidified, Fisher & Paykel Healthcare, Auckland, New Zealand)

Intervention type: DEVICE
Group type: OTHER
Intervention: Nasal high flow cannula (OptiflowTM, MR850 heated humidified, Fisher & Paykel Healthcare, Auckland, New Zealand)
Study: NCT04030754

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: amniotic membrane
Description: amniotic membrane is a biological dressing

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: duoderm dressing
Description: duoderm dressing is a synthetic dressing